Drug duo takes on rare cancers: new hope for HER2 patients
NCT ID NCT06136897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether a combination of two targeted drugs, trastuzumab and pertuzumab, can shrink tumors in patients with HER2-amplified cancers that are not breast, stomach, or colorectal. The drugs block signals that make cancer cells grow and help the immune system attack them. About 35 adults with advanced solid tumors will receive the treatment, and researchers will measure how many patients respond and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab and pertuzumab (antibody drugs that target HER2 protein on cancer cells)
What this could lead to
If successful, this could offer a new treatment option for patients with rare HER2-amplified cancers that are not breast, stomach, or colorectal.
What could go wrong
This is a small, early-phase trial (35 participants) with no control group. The drugs may not work for all cancer types, and side effects like heart problems or infusion reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States